Navigation Links
Hepatitis B Foundation Testifies Before Congressional Appropriation Committee and Urges More Federal Funding for Hepatitis B
Date:3/20/2008

DOYLESTOWN, Pa., March 20 /PRNewswire-USNewswire/ -- Hepatitis B Foundation President Dr. Timothy Block testified about the public health challenge of chronic hepatitis B before the Congressional Appropriations Subcommittee on Labor, Health and Human Services on March 13 in Washington, DC, at the request of Honorable David Obey, chairman, Committee on Appropriations. Dr. Block spoke about the urgent need to strengthen and increase funding for hepatitis B programs at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH).

"The recent crisis in a Nevada clinic, where 40,000 people were placed at risk for infection with hepatitis B and C, is a problem that the CDC thinks might just be the tip of the iceberg," said Dr. Block. "This incident highlights critical deficiencies in our public health and research programs, and if we don't act with urgency, more and more people will suffer."

The Foundation believes that a well-equipped CDC is our best hope to manage the public health problem of hepatitis B. Two million chronically infected Americans are depending upon the NIH to search for new interventions to treat hepatitis B and liver cancer, a fatal outcome of chronic hepatitis B and the fastest growing cancer in the U.S. today. Both the CDC and NIH have performed admirably with the limited resources they are provided; however, much more is needed to achieve effective, lasting solutions.

Dr. Block concluded his testimony by urging the appropriations subcommittee to restore in FY 2009 the overall CDC budget to $7.4 billion with a $50 million increase for the Division of Viral Hepatitis, and to provide a 6.7% increase for the NIH bringing the total to $31.2 billion, including a $40 million annual increase for hepatitis B research.

Chairman David Obey was sympathetic and commented on the importance of restoring cuts to the NIH and CDC budget to address important health issues.

About the Hepatitis B Foundation

The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. For more information, visit http://www.hepb.org or call (215) 489-4900.

Contact: Leah Rice

(215) 340-0480

leah@furiarubel.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Dr. Timothy Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66704 Joan Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66707


'/>"/>
SOURCE Hepatitis B Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
2. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
3. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
4. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... MILPITAS, Calif. , Jan. 17, 2017 /PRNewswire/ ... today announced that it has initiated a global ... PTG-100, an oral peptide that targets alpha4beta7 integrin. ... design study is to evaluate the safety/tolerability and ... colitis patients with moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New Jersey ... appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for its ... of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA located ...
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a ... the U.S. Small Business Administration. The Tibbetts Award honors the Small Business ... […] and are considered the best of the best from the thousands of ...
(Date:1/14/2017)... ... January 14, 2017 , ... ... providing complete end-to-end genome assemblies to researchers around the globe. Long considered ... obstacle in answering a wide range of scientific questions. The announcement was ...
Breaking Biology Technology:
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/4/2017)... 4, 2017  For the thousands of attendees at this year,s International ... connected health and biometric measurement devices and services, will be featuring its ... display in A&D Medical,s special CES Exhibit Suite , the new ... of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):